Affordable Access

deepdyve-link
Publisher Website

Hybrid imaging of the abdomen and pelvis.

Authors
  • Suarez-Weiss, Krista Elise1
  • Herold, Alexander2
  • Gervais, Debra1
  • Palmer, Edwin1
  • Amorim, Bárbara3
  • King, Joseph D1
  • Weier, Li1
  • Shahein, Tajmir1
  • Bernstine, Hanna4
  • Domachevsk, Liran4
  • Cañamaque, Lina Garcia5
  • Herrmann, Ken
  • Umutlu, Lale
  • Groshar, David4
  • Catalano, Onofrio A6, 7, 8
  • 1 Division of Abdominal Radiology, Massachusetts General Hospital, Boston, MA, USA.
  • 2 University of Vienna, Vienna, Austria. , (Austria)
  • 3 Campinas State University, Campinas, Brazil. , (Brazil)
  • 4 Tel Aviv University, Tel Aviv, Israel. , (Israel)
  • 5 HM Hospitales, Madrid, Spain. , (Spain)
  • 6 Division of Abdominal Radiology, Massachusetts General Hospital, Boston, MA, USA. [email protected]
  • 7 University of Naples Parthenope, Naples, Italy. [email protected] , (Italy)
  • 8 Harvard Medical School, Massachusetts General Hospital, 55 Fruits St, Boston, MA, USA. [email protected]
Type
Published Article
Journal
Der Radiologe
Publisher
Springer-Verlag
Publication Date
May 18, 2020
Identifiers
DOI: 10.1007/s00117-020-00661-x
PMID: 32424463
Source
Medline
Keywords
Language
English
License
Unknown

Abstract

Accurate imaging is crucial for lesion detection in abdominal organs, for the noninvasive characterization of focal and diffuse abnormalities, and for surgical planning. To accomplish these tasks, several imaging modalities such as multidetector computer tomography (MDCT), magnetic resonance imaging (MRI) and positron emission tomography/computed tomography (PET/CT) are used for abdominal imaging, providing important morphological, functional or metabolic information. More recently, PET/MRI has been gaining attention due to the possibility of combining high-resolution imaging with metabolic imaging. PET/MRI is a novel hybrid imaging technology that in the near future might play a pivotal role in the clinical management of oncologic and inflammatory abdominopelvic diseases. Despite the still limited number of published clinical studies, PET/MRI has been proven to be at least equivalent to PET/CT and to standalone MRI in a variety of oncologic disease. Moreover, in selected and focused clinical studies, it has been proven to outperform current standard of care imaging, for example, in evaluating cholangiocarcinomas, liver metastases, untreated and treated rectal cancer. This has also had an impact on therapeuticmanagement in some studies. Therefore in some institutions, including those of the authors, PET/MRI is becoming the new standard imaging modality in staging treatment-naïve intrahepatic massforming cholangiocarcinomas and prior to complicated hepatic surgery.

Report this publication

Statistics

Seen <100 times